Henan Real Biotechnology Co., Ltd. (referred to as "Real Biology"), the first approved domestic oral drug developer of COVID-19, submitted an application for IPO to the Hong Kong Stock Exchange on August 4.
It only took 3 weeks for real biology to disclose the data of azivudine III clinical trial and get the approval of increasing COVID-19 's indications to submit the IPO application, which can be described as amazing speed.
On July 15th, Real Biology announced the results of a phase III clinical trial of azivudine in the treatment of COVID-19.
The results showed that the rate of clinical symptom improvement on the 7th day after the first administration in the azivudine group was 40.43%, while that in the placebo group was 10.87%. There was a very significant difference in the median time of clinical symptom improvement between the azivudine group and the placebo group (P value).
On July 25th, the State Drug Administration conditionally approved the application for registration of COVID-19 for additional treatment of azifudine tablets, becoming the first anti-COVID-19 small molecule oral drug approved in China.
On August 2, the real creature held the production ceremony of COVID-19 oral medicine Azvudine tablets, and announced that "Azvudine" was put into production. Wang Chaoyang, founder of real biology, said that the approval of Azvudine anti-COVID-19 indications on the market is an important milestone in the development of real biology.
On August 4, Real Biology submitted an application for listing to the Stock Exchange.
According to the prospectus, True Biology authorized Beijing Union Union to conduct the Azvudine clinical trial in Russia. The Russian phase 3 clinical trial was launched in June 2021 and is expected to be completed by the end of 2022.
In addition, Real Biology also authorized Peking Union and an independent third-party agent to conduct the Azvudine clinical trial in Brazil, where phase 3 clinical trials were launched in June 2021 and are expected to be completed by the end of 2022.
After winning the right to list the first oral drug against COVID-19 in China, on the evening of July 25, Real Biology reached a strategic cooperation with Shanghai Fosun Pharmaceutical. Shanghai Fosun Pharmaceutical Industry, a subsidiary of Shanghai Fosun Pharmaceutical, won the exclusive commercial authorization of Azvudine.
The above commercialization includes distribution, import, export, sales and promotion, and the areas of cooperation include novel coronavirus, AIDS treatment and prevention. The proposed cooperation areas are within China (excluding Hong Kong, Macao and Taiwan) and global regions (except Russia, Ukraine, Brazil and other South American countries and regions). To this end, Shanghai Fosun Pharmaceutical will pay 800 million yuan to the real creature in stages.
At present, American pharmaceutical companies Pfizer Inc and Merck's COVID-19 have been taken orally on the market, but the price is more expensive. The oral drugs of Real Biology, Junshi Biology and other companies are still in clinical trials.
In 2020, 2021 and May before 2022, the "other income and income" of real organisms were 68000, 1.376 million and 8.451 million, with losses of 151 million, 197 million and 218 million respectively. Among them, R & D expenditure is 106 million, 64 million and 114 million respectively. (company research room cookies / editors)